- Home
- SPH vs TRVI Comparison
SPH vs TRVI Comparison
Compare SPH & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPH
- TRVI
- Stock Information
- Founded
- SPH 1945
- TRVI 2011
- Country
- SPH United States
- TRVI United States
- Employees
- SPH N/A
- TRVI N/A
- Industry
- SPH Other Specialty Stores
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SPH Consumer Discretionary
- TRVI Health Care
- Exchange
- SPH Nasdaq
- TRVI Nasdaq
- Market Cap
- SPH 1.2B
- TRVI 1.1B
- IPO Year
- SPH 1996
- TRVI 2019
- Fundamental
- Price
- SPH $18.58
- TRVI $9.82
- Analyst Decision
- SPH
- TRVI Strong Buy
- Analyst Count
- SPH 0
- TRVI 9
- Target Price
- SPH N/A
- TRVI $20.72
- AVG Volume (30 Days)
- SPH 105.7K
- TRVI 2.3M
- Earning Date
- SPH 11-13-2025
- TRVI 11-05-2025
- Dividend Yield
- SPH 6.98%
- TRVI N/A
- EPS Growth
- SPH N/A
- TRVI N/A
- EPS
- SPH 1.49
- TRVI N/A
- Revenue
- SPH $1,429,783,000.00
- TRVI N/A
- Revenue This Year
- SPH $10.99
- TRVI N/A
- Revenue Next Year
- SPH N/A
- TRVI N/A
- P/E Ratio
- SPH $12.51
- TRVI N/A
- Revenue Growth
- SPH 6.29
- TRVI N/A
- 52 Week Low
- SPH $16.92
- TRVI $2.36
- 52 Week High
- SPH $22.24
- TRVI $10.16
- Technical
- Relative Strength Index (RSI)
- SPH N/A
- TRVI 65.50
- Support Level
- SPH N/A
- TRVI $9.30
- Resistance Level
- SPH N/A
- TRVI $10.16
- Average True Range (ATR)
- SPH 0.00
- TRVI 0.49
- MACD
- SPH 0.00
- TRVI 0.08
- Stochastic Oscillator
- SPH 0.00
- TRVI 81.60
About SPH Suburban Propane Partners L.P.
Suburban Propane Partners LP distributes propane, fuel oil, and other refined fuels to customers in the East Coast and West Coast regions of the United States. Other operations include natural gas and electricity marketing in the deregulated New York and Pennsylvania markets. The company operates in three segments: Propane; Fuel Oil and Refined Fuels; and Natural Gas and Electricity. It generates maximum revenue from Propane segment.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.